ClinicalTrials.gg
RecruitingNCT07227116ESCALATEUpdated Nov 12, 2025

Evaluating the Status of Complex Aneuploidy to Locate Additional Transferrable Embryos

An observational study in Complex Aneuploidy and Chaotic Aneuploidy, sponsored by Shady Grove Fertility Reproductive Science Center. Recruiting at 12 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Shady Grove Fertility Reproductive Science Center · Observational

From the registry’s dates

  • Primary completion was expected by Apr 2026, 7 months ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
280
Sex
All
01

Study summary

This study aims to evaluate the reproductive potential of embryos classified as "complex aneuploid" (involving three or more abnormal chromosomes) or "chaotic" (six or more abnormal chromosomes) through preimplantation genetic testing for aneuploidy (PGT-A). Specifically, we seek to determine whether embryos initially reported as having multiple chromosomal abnormalities might still have the potential for normal chromosomal composition, the opportunity for transfer, and ultimately, the potential to achieve a live birth through re-biopsy and reanalysis.

Key Information:

This portion of the study seeks your consent for the re-biopsy and genetic reanalysis of the embryos only. It does not yet include consent for potential future transfer.

Participation remains completely voluntary, and your decision will not affect your current or future care.

We deeply appreciate your support and commitment to advancing fertility research.

Read the detailed description

Recently, the term "chaotic" has come into the PGT-A reporting lexicon, defined (perhaps arbitrarily) as 6 or more aneuploidies detected. Complex aneuploidy refers to embryos with multiple chromosomal aneuploidies. In one large study, complex aneuploidy at the cleavage stage was found in 41% of embryos overall, 29% of embryos in women 27-37 years old, and 45% of embryos in women 38-45 years old. By the blastocyst stage, only 10% of all embryos were complex aneuploid, with 13.7% of embryos in women aged 38-47 years compared to 4.5% in women aged 27-37 years demonstrating complex aneuploidy. Multiple aneuploidies were also detected in a retrospective study of 1502 spontaneous abortions, with 4.6% of cases showing double aneuploidy and only 0.4% showing 3 or more aneuploidies (2).

The high rate of complex aneuploidy in cleavage and blastocyst stage embryos even among young patients suggests multiple mitotic errors in the first few cell divisions, which would likely lead to developmental arrest (2). Therefore, if transferred, such embryos would be expected not to implant or to miscarry. Historically, embryos with multiple chromosomal abnormalities have therefore been de-selected for transfer or even discarded. However, recently Lin et al. reported a healthy live birth following chaotic embryo transfer (3), calling into question the assumed non-viability of chaotic embryos. Might some of these embryos correct multiple aneuploidies and become euploid? It is plausible that any euploid population of cells could have a higher survival rate and a higher mitotic rate, and if abnormal cells undergo apoptosis, a euploid embryo could result. This could explain the low rate of complex aneuploidy seen in miscarriages. An additional explanation is that imperfections in the biopsy, amplification, and/or NGS PGT-A process occasionally lead to noisy reads, that are interpreted as multiple chromosomal abnormalities, but actually reflect artifact. For such embryos, re- testing may result in euploid results.

Small studies (published in abstract form only) have evaluated the reproducibility of chaotic results from NGS-based PGT-A. A retrospective cohort study evaluated 58 'chaotic' embryos via PGT-A of re-biopsy samples. Thirty-eight percent (n=22) of embryos had euploid re-biopsy results (4). Our group reported re-biopsy of 64 embryos initially classified as chaotic and identified 17% (n=11) of embryos in the cohort as euploid and only 67% concordance between initial and re-biopsy sample results (5). Four blastocysts with euploid results on re- biopsy were transferred, resulting in two ongoing pregnancies. Furthermore, we have pooled data from multiple IVF clinics within our network that have conducted re-biopsy of embryos with multiple aneuploidies and found that overall, 22% had euploid PGT-A results on re-biopsy (Background Table, unpublished data).

In anticipation of conducting a prospective observational study to characterize the nature of PGT-A results indicating 3 or more aneuploidies, we have begun to catalog and hold these embryos in storage. To date, 112 patients with have explicitly expressed interest in contributing 128 embryos resulted as 'chaotic' or 'complex aneuploid' of 3-5 chromosomes, for the purposes of this research, and we anticipate identifying multiples of this number upon a

retrospective database search and with prospective accumulation of additional PGT-A results. Following a retrospective database search, we have identified a total of 274 'chaotic' and 5251 'complex aneuploid' embryos having been reported using NGS based PGT-A. Limited data exist on the reproductive potential of embryos classified as having multiple chromosomal abnormalities, and preliminary data, including from our center, suggest a high false positive rate. The large volume of ART performed within our network represents a unique opportunity to characterize the clinical significance of these results, in the hopes of minimizing embryo wastage and maximizing live birth from IVF cycles using PGT-A.

The aim of this study is to evaluate the reproductive potential of embryos classified as "complex aneuploid" of three or more chromosomes or "chaotic" on initial trophectoderm biopsy sample analyzed by next generation sequencing based preimplantation genetic testing for aneuploidy. We plan to do this by prospectively enrolling patients with embryos classified as such, re-biopsy of the embryos, and analysis of repeat biopsy samples. We also plan to have an independent, blinded geneticist make diagnoses, as possible, based on the NGS profiles.

02

Conditions studied

  • Complex Aneuploidy
  • Chaotic Aneuploidy

Browse trials for

Keywords

  • Chaotic, Complex, Aneuploidies, Embryos
03

In context

Aneuploidy

73 studies on the registry are indexed under Aneuploidy; 10 are open to participants now.

This study's planned enrollment of 280 is below the median of 325 across 38 observational studies indexed under Aneuploidy.

Browse Aneuploidy studies →

Lead sponsor

Shady Grove Fertility Reproductive Science Center is the lead sponsor of 10 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

All patients with one or more embryos in storage that meet criteria for Chaotic or Complex Aneuploidy by PGT-A with NGS

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Having ≥ 1 embryo classified as whole chromosome chaotic or complex aneuploid of 3 or more chromosomes following preimplantation genetic testing for aneuploidy using an NGS based platform Signed

Exclusion criteria

Exclusion Criteria:

  • Embryos not meeting complex/chaotic criteria Patients declining consent
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
280 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Multiple Aneuploidy Embryos

    Embryos identified by PGT-A as having multiple chromosomal aneuploidies. DNA from trophectoderm re-biopsy samples will be retained by the testing laboratory for confirmatory analysis and quality control under IRB-approved protocols.

06

What researchers measure

Primary outcomes

  1. Reproducibility

    To evaluate embryos with 3 or more chromosomes deemed aneuploid with NGS-based PGT-A by performing repeat biopsy and analyzing with NGS.

    Time frame: one year

07

Study locations

12 of 12 sites recruiting
  • IVF Florida Reproductive Associates
    Margate, Florida 33063, United States
    Recruiting
    • Kathy Miller, PhD, HCLD · Contact3015451423
  • Shady Grove Fertility
    Atlanta, Georgia 30342, United States
    Recruiting
  • Fertility Center of Illinois
    Highland Park, Illinois 60035, United States
    Recruiting
  • Shady Grove Fertility
    Rockville, Maryland 20850, United States
    Recruiting
  • Shady Grove Fertility
    Towson, Maryland 33607, United States
    Recruiting
  • Shady Grove Fertility
    Cary, North Carolina 27519, United States
    Recruiting
  • Shady Grove Fertility
    Cary, North Carolina 27519, United States
    Recruiting
    • · Contact3015451423
  • Shady Grove Fertility
    Chesterbrook, Pennsylvania 19087, United States
    Recruiting
  • Shady Grove Fertility
    Fairfax, Virginia 22031, United States
    Recruiting
  • Shady Grove Fertility
    Norfolk, Virginia 23507, United States
    Recruiting
  • Shady Grove Fertility
    Richmond, Virginia 23235, United States
    Recruiting
  • SGFertility Chile Medicina Reproductiva
    Santiago, Santiago Metropolitan 7630000, Chile
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2025; primary completion for Apr 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Nov 12, 2025
StartEst.
Nov 1, 2025
Primary completionEst.
Apr 2026
CompletionEst.
Jun 2026
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07227116
Lead sponsor
Shady Grove Fertility Reproductive Science Center
Responsible party
Benjamin Harris (MD, Shady Grove Fertility Reproductive Science Center) — Principal investigator
First posted
Nov 12, 2025
Start date
Nov 1, 2025 (estimated)
Primary completion
Apr 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Nov 12, 2025

Study contacts

SGF Research Team SGF Research Team
Contact
SGFClinicalResearchTeam@sgfertility.com
(301) 545-1423
Benjamin S Harris, MD, MPH
Contact
benjamin.harris@sgfertility.com
Kate Devine, MD
study director · Shady Grove Fertility
Benjamin S Harris, MD, MPH
principal investigator · Shady Grove Fertility

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion